Tyers Asset Management LLC bought a new position in Gossamer Bio Inc (NASDAQ:GOSS) in the first quarter, HoldingsChannel.com reports. The firm bought 25,872 shares of the company’s stock, valued at approximately $561,000.

Other large investors have also recently added to or reduced their stakes in the company. Federated Investors Inc. PA purchased a new stake in Gossamer Bio in the first quarter worth $15,992,000. Dean Capital Investments Management LLC purchased a new stake in Gossamer Bio in the first quarter worth $725,000. Victory Capital Management Inc. purchased a new stake in Gossamer Bio in the first quarter worth $18,649,000. Rhumbline Advisers purchased a new stake in Gossamer Bio in the first quarter worth $271,000. Finally, Creative Planning purchased a new stake in Gossamer Bio in the first quarter worth $260,000. 52.76% of the stock is owned by institutional investors and hedge funds.

Gossamer Bio stock opened at $20.26 on Friday. Gossamer Bio Inc has a one year low of $15.59 and a one year high of $25.06. The company has a quick ratio of 11.37, a current ratio of 19.79 and a debt-to-equity ratio of 0.02.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.90) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($0.27). As a group, equities analysts anticipate that Gossamer Bio Inc will post -2.61 EPS for the current fiscal year.

GOSS has been the subject of a number of recent research reports. Bank of America initiated coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued a “buy” rating and a $30.00 target price for the company. Barclays initiated coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 target price for the company. Leerink Swann initiated coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating for the company. Svb Leerink initiated coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 target price for the company. Finally, Evercore ISI assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 target price for the company. Six analysts have rated the stock with a buy rating, Gossamer Bio currently has an average rating of “Buy” and an average target price of $28.00.

ILLEGAL ACTIVITY WARNING: “25,872 Shares in Gossamer Bio Inc (NASDAQ:GOSS) Purchased by Tyers Asset Management LLC” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2019/06/16/25872-shares-in-gossamer-bio-inc-nasdaqgoss-purchased-by-tyers-asset-management-llc.html.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Article: What are the benefits of investing in REITs?

Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio Inc (NASDAQ:GOSS).

Institutional Ownership by Quarter for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.